USD
+$0.00
(+0.00%
)At Close (As of Nov 14, 2025)
$7.71M
Market Cap
-
P/E Ratio
-3.13
EPS
$6.90
52 Week High
$1.69
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.6K |
| Total Revenue | $11K |
| Cost Of Revenue | $4.4K |
| Costof Goods And Services Sold | $4.4K |
| Operating Income | -$5.7M |
| Selling General And Administrative | $3.2M |
| Research And Development | $2.4M |
| Operating Expenses | $5.8M |
| Investment Income Net | - |
| Net Interest Income | $250K |
| Interest Income | $250K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $110K |
| Income Before Tax | -$5.5M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$5.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$5.7M |
| Ebitda | -$5.6M |
| Net Income | -$5.5M |
| Field | Value (USD) |
|---|---|
| Total Assets | $6.7M |
| Total Current Assets | $6.1M |
| Cash And Cash Equivalents At Carrying Value | $5.9M |
| Cash And Short Term Investments | $5.9M |
| Inventory | $2.2K |
| Current Net Receivables | - |
| Total Non Current Assets | $534K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $531K |
| Intangible Assets Excluding Goodwill | $531K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $0 |
| Other Current Assets | $193K |
| Other Non Current Assets | - |
| Total Liabilities | $328K |
| Total Current Liabilities | $328K |
| Current Accounts Payable | $274K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $14K |
| Total Non Current Liabilities | $0 |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $14K |
| Other Current Liabilities | $54K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $6.3M |
| Treasury Stock | - |
| Retained Earnings | -$65M |
| Common Stock | $1.7K |
| Common Stock Shares Outstanding | $1.5M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$5.3M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $110K |
| Capital Expenditures | $200K |
| Change In Receivables | - |
| Change In Inventory | $4.4K |
| Profit Loss | - |
| Cashflow From Investment | $6.3M |
| Cashflow From Financing | $1.5M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$175K |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$5.5M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $6.6K |
| Total Revenue | $11K |
| Cost Of Revenue | $4.4K |
| Costof Goods And Services Sold | $4.4K |
| Operating Income | -$5.7M |
| Selling General And Administrative | $3.2M |
| Research And Development | $2.4M |
| Operating Expenses | $5.8M |
| Investment Income Net | - |
| Net Interest Income | $250K |
| Interest Income | $250K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $110K |
| Income Before Tax | -$5.5M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$5.5M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$5.7M |
| Ebitda | -$5.6M |
| Net Income | -$5.5M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Creative Medical Technology Holdings, Inc. (CELZ) is an innovative biotechnology company headquartered in Phoenix, Arizona, dedicated to advancing regenerative medicine through the development of cutting-edge adult stem cell therapies. The firm concentrates on critical sectors such as immunology, urology, orthopedics, and neurology, targeting unmet medical needs and striving to enhance patient outcomes. With a robust research pipeline and a commitment to leveraging the unique properties of stem cells, CELZ is well-positioned to lead transformative changes in treatment paradigms within the healthcare industry.